Contrasting Kymera Therapeutics (NASDAQ:KYMR) and MiNK Therapeutics (NASDAQ:INKT)

Kymera Therapeutics (NASDAQ:KYMR) and MiNK Therapeutics (NASDAQ:INKT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares Kymera Therapeutics and MiNK Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$88.55 million	31.93	-$146.96 million	($2.51)	-18.36
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.60)	-1.29

MiNK Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-178.27%	-28.88%	-22.37%
MiNK Therapeutics	N/A	N/A	-233.85%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Kymera Therapeutics and MiNK Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0	4	8	1	2.77
MiNK Therapeutics	0	0	1	0	3.00

Kymera Therapeutics presently has a consensus target price of $48.67, indicating a potential upside of 5.61%. MiNK Therapeutics has a consensus target price of $9.00, indicating a potential upside of 1,060.54%. Given MiNK Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Kymera Therapeutics.

Institutional and Insider Ownership

2.9% of MiNK Therapeutics shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 17.8% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Kymera Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.

Summary

MiNK Therapeutics beats Kymera Therapeutics on 9 of the 14 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.